Literature DB >> 8410082

Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study.

O Andersen1, P E Lygner, T Bergström, M Andersson, A Vahlne.   

Abstract

A neurological surveillance was combined with prospective recording of upper respiratory and gastrointestinal infections and serological diagnosis of five common viral infections in 60 benign multiple sclerosis patients, with a mean follow-up of 31 months. During 4-week at risk (AR) periods encompassing common infections, a significant excess of MS relapses was found in the AR period, with a relative risk of 1.3. A seasonal variation of the MS relapse rate was found with a minimum in summer. There was a significant correlation between the number of AR relapses and the number of common infections per month explaining the periannual distribution of relapses. The non-AR relapses showed no seasonal variation. There was a significant correlation between adenovirus CF titre rises associated with upper respiratory infections and the occurrence of a major MS relapse in the AR period (n = 7), while influenza infections were not followed by a major MS relapse (n = 6). Linear homologies have been demonstrated between adenovirus and basic myelin protein. The epidemiological approach is essential to our understanding of systemic antigens triggering multiple sclerosis activity.

Entities:  

Mesh:

Year:  1993        PMID: 8410082     DOI: 10.1007/bf00867354

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  24 in total

1.  INFECTION AND IMMUNIZATION IN MULTIPLE SCLEROSIS.

Authors:  W A SIBLEY; J M FOLEY
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

2.  The recognition and estimation of cyclic trends.

Authors:  J H EDWARDS
Journal:  Ann Hum Genet       Date:  1961-05       Impact factor: 1.670

3.  The seasonal incidence of onset and exacerbations in multiple sclerosis.

Authors:  K SCHAPIRA
Journal:  J Neurol Neurosurg Psychiatry       Date:  1959-11       Impact factor: 10.154

4.  Incidence of MS during two fifteen-year periods in the Gothenburg region of Sweden.

Authors:  A Svenningsson; B Runmarker; J Lycke; O Andersen
Journal:  Acta Neurol Scand       Date:  1990-09       Impact factor: 3.209

5.  The multiple causes of multiple sclerosis: the importance of age of infections in childhood.

Authors:  E C Alvord; U Jahnke; E H Fischer; M W Kies; B F Driscoll; D A Compston
Journal:  J Child Neurol       Date:  1987-10       Impact factor: 1.987

Review 6.  HLA associations in multiple sclerosis: implications for immunopathogenesis.

Authors:  F Vartdal
Journal:  Res Immunol       Date:  1989-02

7.  Sequence homology between certain viral proteins and proteins related to encephalomyelitis and neuritis.

Authors:  U Jahnke; E H Fischer; E C Alvord
Journal:  Science       Date:  1985-07-19       Impact factor: 47.728

8.  Myxofibrosarcoma. A malignant soft tissue tumor of fibroblastic-histiocytic origin. A clinicopathologic and prognostic study of 110 cases using multivariate analysis.

Authors:  C Merck; L Angervall; L G Kindblom; A Odén
Journal:  Acta Pathol Microbiol Immunol Scand Suppl       Date:  1983

9.  Restricted dissemination of clinically defined attacks in an MS incidence material.

Authors:  O Andersen
Journal:  Acta Neurol Scand Suppl       Date:  1980

10.  Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity.

Authors:  R S Fujinami; M B Oldstone
Journal:  Science       Date:  1985-11-29       Impact factor: 47.728

View more
  85 in total

Review 1.  The genetic epidemiology of multiple sclerosis.

Authors:  A Compston
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-10-29       Impact factor: 6.237

2.  Breakdown of the blood-retinal barrier induced by activated T cells of nonneural specificity.

Authors:  P Hu; J D Pollard; T Chan-Ling
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

3.  Humoral immunity against glutamic acid decarboxylase and tyrosine phosphatase IA-2 in Lambert-Eaton myasthenic syndrome.

Authors:  L Hermitte; N Martin-Moutot; J Boucraut; R Barone; C Atlan-Gepner; M Seagar; J Pouget; J P Kleisbauer; F Couraud; B Vialettes
Journal:  J Clin Immunol       Date:  2000-07       Impact factor: 8.317

4.  Crossreactive recognition of viral, self, and bacterial peptide ligands by human class I-restricted cytotoxic T lymphocyte clonotypes: implications for molecular mimicry in autoimmune disease.

Authors:  I S Misko; S M Cross; R Khanna; S L Elliott; C Schmidt; S J Pye; S L Silins
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

5.  Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study.

Authors:  J Lycke; B Svennerholm; E Hjelmquist; L Frisén; G Badr; M Andersson; A Vahlne; O Andersen
Journal:  J Neurol       Date:  1996-03       Impact factor: 4.849

Review 6.  Mechanisms and implications of adaptive immune responses after traumatic spinal cord injury.

Authors:  D P Ankeny; P G Popovich
Journal:  Neuroscience       Date:  2008-07-04       Impact factor: 3.590

7.  A controlled study of potential risk factors preceding exacerbation in multiple sclerosis.

Authors:  C Gasperini; M G Grasso; M Fiorelli; E Millefiorini; S Morino; A Anzini; A Colleluori; M Salvetti; C Buttinelli; C Pozzilli
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-09       Impact factor: 10.154

Review 8.  Genetic epidemiology of multiple sclerosis.

Authors:  A Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-06       Impact factor: 10.154

Review 9.  Mechanisms of action of interferon-beta in multiple sclerosis.

Authors:  B G Arnason; A Dayal; Z X Qu; M A Jensen; K Genç; A T Reder
Journal:  Springer Semin Immunopathol       Date:  1996

Review 10.  Infection risk in patients on multiple sclerosis therapeutics.

Authors:  Eric M Williamson; Joseph R Berger
Journal:  CNS Drugs       Date:  2015-03       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.